RGBiotech - SLAMF7 (CS1) Chimeric Antigen Receptor (CAR): A Comprehensive Guide and Our Service & Product Introduction

		Find Products & Services By Categories. Search
Home Products & Services Support About Us Contact Us

Home -> Support -> Applications ->SLAMF7 (CS1) Chimeric Antigen Receptor (CAR)

Quick Inquiry

SLAMF7 (CS1) Chimeric Antigen Receptor (CAR): A Comprehensive Guide and Our Service & Product Introduction

SLAMF7 (CS1, CD319, CRACC), a member of the signaling lymphocytic activation molecule (SLAM) family, is a key tumor-associated antigen (TAA) with high specificity in hematological malignancies, especially multiple myeloma. RGBiotech is dedicated to providing high-quality SLAMF7 (CS1) chimeric antigen receptor (CAR) expression plasmid vectors and professional custom vector construction services, supporting researchers and biopharmaceutical enterprises in accelerating the development of CAR-T/CAR-NK therapies. If you are interested in our SLAMF7 (CS1) CAR expression plasmid vectors or custom services, or have any questions about SLAMF7 CAR research (e.g., fratricide control, CAR structure optimization), please feel free to contact us at admin@rgbiotech.com. Our professional team will provide you with high-quality products and services, helping you accelerate the progress of your research and development.

Our SLAMF7 (CS1) CAR Expression Plasmid Vector Products and Custom Services

RGBiotech provides a full range of SLAMF7 (CS1) CAR expression plasmid vectors, covering 1st to 5th generation CARs, with diverse vector backbones and rich functional modifications, to meet the needs of different research stages (in vitro experiments, in vivo animal models, preclinical trials). At the same time, we provide professional custom plasmid vector construction services, tailoring personalized solutions according to your research needs, accelerating your research progress. Our products include lentiviral vectors (e.g., pLenti-CMV-SLAMF7-GFP-Puro) and other vector types, supporting various experimental requirements.

Item Name	Item No.	Price	Description
CS1 scFv-CD3ζ (1st) CAR Expression Plasmid	PCAR-109	Inquiry	See More
CS1 scFv-CD28-CD3ζ (2nd) CAR Expression Plasmid	PCAR-110	Inquiry	See More
CS1 scFv-4-1BB-CD3ζ (2nd) CAR Expression Plasmid	PCAR-111	Inquiry	See More
CS1 scFv-CD28-4-1BB-CD3ζ (3rd) CAR Expression Plasmid	PCAR-112	Inquiry	See More
CS1 scFv-CD28-OX40-CD3ζ (3rd) CAR Expression Plasmid	PCAR-113	Inquiry	See More
CS1 scFv-CD28-CD27-CD3ζ (3rd) CAR Expression Plasmid	PCAR-114	Inquiry	See More

RGBiotech provides SLAMF7 (CS1) CAR expression plasmid vectors covering all generations (1st to 5th), meeting different research needs and application scenarios, including basic research and preclinical trials.
1) 1st Generation SLAMF7 (CS1) CAR: Only contains the CD3ζ intracellular signal domain. It can mediate the activation of T cells and kill SLAMF7-positive tumor cells, but lacks co-stimulatory signals, resulting in weak T cell proliferation ability, short survival time, and limited anti-tumor efficacy. Suitable for preliminary research on SLAMF7 targeting.
2) 2nd Generation SLAMF7 (CS1) CAR: Adds one co-stimulatory domain (CD28 or 4-1BB) based on the 1st generation. CD28 co-stimulation enhances T cell activation and proliferation, while 4-1BB co-stimulation improves T cell persistence and memory formation, significantly enhancing anti-tumor efficacy. It is the most widely used generation in current SLAMF7 CAR research and clinical trials, with lentiviral vectors often used for stable expression under the control of the EF1α promoter.
3) 3rd Generation SLAMF7 (CS1) CAR: Contains two co-stimulatory domains (e.g., CD28+4-1BB, CD28+OX40, 4-1BB+OX40). It integrates the advantages of different co-stimulatory signals, further enhancing T cell activation, proliferation, persistence, and anti-tumor activity, and is suitable for the treatment of refractory and relapsed multiple myeloma.
4) 4th Generation SLAMF7 (CS1) CAR (Armored CAR): On the basis of the 3rd generation, it is engineered to express cytokines (IL-12, IL-15, IL-18) or immune checkpoint inhibitors (PD-1 scFv, CTLA-4 scFv). It can remodel the tumor microenvironment, overcome immune suppression, and enhance the anti-tumor effect of CAR-T cells, especially suitable for SLAMF7-positive solid tumors with complex microenvironments.
5) 5th Generation SLAMF7 (CS1) CAR (Universal CAR): Optimized for off-the-shelf therapy, including allogeneic CAR-T cells (edited by CRISPR/Cas9 to knock out SLAMF7, TCR, or HLA genes) and universal CAR structures (e.g., bispecific CAR, switchable CAR). It solves the problem of donor shortage and reduces the risk of graft-versus-host disease (GVHD), accelerating the clinical transformation of SLAMF7 CAR therapy.

Product Features

1) Comprehensive generations coverage: Provide 1st to 5th generation SLAMF7 (CS1) CAR expression plasmids, with optional co-stimulatory domains (CD28, 4-1BB, OX40, etc.), to meet different research needs for CAR function.
2) Diverse vector backbones: Cover non-viral vectors (plasmid, transposon), lentiviral vectors (LV), retroviral vectors (RV), and adeno-associated viral vectors (AAV), with different backbones suitable for different cell transfection methods and application scenarios. For example, lentiviral vectors are suitable for stable expression of SLAMF7 CAR in T/NK cells, AAV vectors for in vivo delivery, and non-viral vectors for safe and low-toxicity research.
3) Optimized promoters: Select high-efficiency promoters according to different cell types, including CMV promoter (universal high-expression), EF1α promoter (stable expression in mammalian cells, commonly used for SLAMF7 CAR expression), PGK promoter (low-toxicity and stable expression), and T7 promoter (for in vitro transcription), ensuring high-efficiency expression of SLAMF7 CAR in target cells (T cells, NK cells, cell lines).
4) Rich fluorescent markers: Optional fluorescent markers (GFP, RFP) for convenient detection of CAR expression efficiency by flow cytometry, fluorescence microscopy, etc. The fluorescent marker can be linked to the CAR gene through a 2A peptide (P2A, T2A), ensuring synchronous expression of CAR and fluorescent protein. For example, our lentiviral SLAMF7 CAR vectors can be designed with C-terminal GFP tags for easy detection.
5) Multiple antibiotic selection markers: Provide common antibiotic selection markers (Puromycin, Hygromycin, Neomycin, Blasticidin, Zeocin) suitable for mammalian cell screening, improving the efficiency of positive cell selection.
6) Sequence verification: To ensure the quality and reliability of our products, all SLAMF7 (CS1) CAR expression plasmid vectors undergo strict quality control, covering the following aspects. We provide full-length CAR sequencing of the plasmid by Sanger method, ensuring 100% concordance with the theoretical reference sequence.
7) Customizable: According to your research needs, we can customize the CAR structure (scFv clone, co-stimulatory domain, signal domain), vector backbone, promoter, fluorescent marker, and selection marker, providing personalized solutions. For example, we can design fratricide-resistant SLAMF7 CAR vectors or dual-target SLAMF7/BCMA CAR vectors.
8) Cost-effective: Provide high-quality products at competitive prices, and support bulk purchase with preferential policies, suitable for long-term research and large-scale experiments (e.g., preclinical animal models, high-throughput screening).

Product Applications

1) Basic research: Study the mechanism of SLAMF7 CAR-mediated anti-tumor immunity, optimize the structure and function of SLAMF7 CAR (e.g., reducing fratricide), and explore the interaction between SLAMF7 CAR-T cells and tumor cells/tumor microenvironment.
2) Preclinical research: Construct SLAMF7 CAR-T/CAR-NK cells, evaluate their anti-tumor efficacy and safety in vitro (cell killing assay, proliferation assay, cytokine secretion assay) and in vivo (animal tumor models such as nude mice, humanized mice) for multiple myeloma and other hematological malignancies.
3) Drug development: Support the research and development of SLAMF7 CAR-T/CAR-NK drugs, including vector optimization, process development, and preclinical evaluation, especially for off-the-shelf allogeneic CAR-T products.
4) Teaching and training: Used for teaching experiments in immunology, molecular biology, and oncology, helping students understand CAR technology and its application in tumor immunotherapy, especially in the context of multiple myeloma.

Custom Vector Construction Services

In addition to standard products, we also provide professional SLAMF7 (CS1) CAR plasmid vector custom construction services, tailoring personalized solutions according to your specific research needs. Our custom team has rich experience in SLAMF7 CAR vector construction, familiar with the design and optimization of different generations of CARs, and can provide professional suggestions to avoid experimental risks.
1) CAR structure customization: Customize anti-SLAMF7 scFv, co-stimulatory domains and signal domains, optimizing the CAR structure to improve its anti-tumor activity, persistence, and safety, and reduce fratricide risks.
2) Vector backbone customization: Select or modify vector backbones (non-viral, lentiviral, retroviral, AAV) according to your transfection method and application scenario.
3) Functional element customization: Customize promoters, fluorescent markers, antibiotic selection markers, safety switches (iC9, RQR8), cytokines (IL-12, IL-15), or immune checkpoint inhibitors (PD-1 scFv) according to your needs, realizing multi-functional modification of the vector. For example, we can add GFP tags and Puromycin resistance to lentiviral vectors for easy detection and selection.

Introduction of SLAMF7 (CS1)

SLAMF7, also known as CS1 (CD319, CRACC), is encoded by the SLAMF7 gene (NCBI Gene ID: 57823; Uniprot ID: Q9NYY1; OMIM: 606625). Located on human chromosome 1 (1q23.1, chr 1: 171.46–171.48 mb), the SLAMF7 gene spans approximately 10 kb, contains 5 exons, and encodes a 234-amino-acid transmembrane glycoprotein. As a highly conserved gene across vertebrates, SLAMF7 is widely expressed in immune cells, with its sequence and functional domains highly conserved, laying a solid foundation for cross-species research and preclinical trials.

SLAMF7 (CS1) protein is a single-pass type I transmembrane glycoprotein with a molecular weight of approximately 23.3 kDa, consisting of three functional domains that determine its biological activity and antigenicity. 1) Extracellular N-terminal domain (23–225 amino acids): Contains one Ig-like C2-type (immunoglobulin-like) domain, which serves as the binding site for CAR single-chain variable fragments (scFv) and mediates interactions with other SLAM family members. 2) Transmembrane domain: A single α-helical transmembrane segment that anchors the protein to the cell membrane, ensuring its stable surface expression on target cells. 3) Cytoplasmic C-terminal domain: Contains immunoreceptor tyrosine-based switch motifs (ITSM), which can recruit signaling lymphocyte activation molecule (SLAM)-associated protein (SAP/SH2D1A) and regulate intracellular signal transduction. The extracellular domain of SLAMF7 is glycosylated, which is crucial for its antigenicity and binding ability to CARs. This structural feature makes it an ideal target for the design of anti-SLAMF7 scFv in CAR construction, ensuring specific recognition of tumor cells.

SLAMF7 (CS1) is a multifunctional immune regulatory protein that acts as both a receptor and a signaling molecule, participating in multiple physiological and pathological processes, especially in immune regulation and tumor progression.
1) Immune cell regulation: It is mainly expressed on natural killer (NK) cells, activated B cells, monocytes, and some T cells, regulating the activation, proliferation, and cytotoxicity of immune cells. SLAMF7 positively regulates NK cell functions through the adaptor EAT-2, while exerting inhibitory effects in T cells (which lack EAT-2) and in the absence of EAT-2 in NK cells.
2) Cell adhesion and communication: Mediates adhesion between immune cells and between immune cells and tumor cells, participating in intercellular signal transduction and promoting the interaction between tumor cells and the tumor microenvironment.
3) Tumor progression: In tumor cells (especially multiple myeloma), SLAMF7 promotes cell proliferation, survival, and migration, and participates in immune escape by regulating the expression of immune checkpoint molecules and cytokines.
4) Signal transduction: Through its cytoplasmic ITSM motifs, SLAMF7 recruits adaptor proteins (SAP, EAT-2) to activate downstream signaling pathways (PI3K/Akt, MAPK), regulating cell survival and cytotoxicity.

SLAMF7 (CS1) has a relatively restricted tissue distribution, with distinct expression patterns in normal and tumor tissues, providing a favorable safety window for targeted immunotherapy.
1) Normal tissues: Low to moderate expression in immune-related tissues and cells, including spleen, lymph nodes, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung, and trachea. Specifically, it is expressed in NK cells, activated B cells, monocytes, and NK cell lines, but not in promyelocytic cells, B-cell lines, or T-cell lines. Its low expression in non-immune normal tissues minimizes off-target toxicity risks.
2) Tumor tissues: High and specific expression in a variety of hematological malignancies, especially multiple myeloma (MM) - it is expressed in almost 100% of primary and relapsed MM cases, and is more stable than the traditional plasma cell marker CD138, allowing robust isolation of malignant plasma cells even from delayed or cryopreserved samples. It is also expressed in other hematological malignancies such as non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL), as well as some solid tumors (e.g., ovarian cancer, lung cancer) at low levels.

SLAMF7 (CS1) is closely associated with the occurrence, development, and prognosis of multiple diseases, mainly focusing on hematological malignancies, especially multiple myeloma.
1) Hematological malignancies: Multiple myeloma (the most closely related disease) - SLAMF7 expression is positively correlated with MM progression, drug resistance, and poor prognosis. It is also involved in the development of NHL, AML, CLL, and other hematological tumors by regulating immune cell function and tumor cell survival.
2) Immune-related diseases: Autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) - abnormal expression of SLAMF7 leads to dysregulation of immune cell activation, contributing to the occurrence of autoimmune responses.
3) Other diseases: Inflammatory diseases (e.g., chronic inflammation of the digestive tract) - SLAMF7 participates in the regulation of inflammatory responses by mediating the interaction between immune cells and inflammatory cells.

Introduction of SLAMF7 (CS1) Chimeric Antigen Receptor (CAR)

SLAMF7 (CS1) CAR is a chimeric antigen receptor specifically targeting the SLAMF7 (CS1) antigen, which is engineered to express on the surface of immune cells (T cells, NK cells) through plasmid vectors. It enables immune cells to specifically recognize and kill SLAMF7-positive tumor cells in a major histocompatibility complex (MHC)-independent manner. The core structure of SLAMF7 (CS1) CAR consists of four parts: extracellular antigen-binding domain (anti-SLAMF7 scFv), hinge region, transmembrane domain, and intracellular signal domain. Different generations of CARs are distinguished by the number and type of intracellular signal domains, with distinct functional characteristics adapted to different research and application scenarios.

Current Research Achievements

In recent years, SLAMF7 (CS1) CAR research has made remarkable progress, especially in the treatment of multiple myeloma, with a large number of preclinical and clinical studies verifying its safety and efficacy, and it has become a promising alternative to classic BCMA-CAR therapy.
1) Preclinical research: SLAMF7 CAR-T/CAR-NK cells have shown strong specific killing activity against SLAMF7-positive tumor cells (especially multiple myeloma cells) in vitro and in vivo. For example, second-generation SLAMF7 CAR-T cells containing a 4-1BB co-stimulatory domain, CD8α hinge and transmembrane domain, and CD3ζ signaling domain have shown potent anti-tumor activity in preclinical models. Additionally, SLAMF7 CAR-T cells can trigger selective fratricide of SLAMF7-high lymphocytes (NK cells, CD4+ and CD8+ T cells, B cells) while preserving functional lymphocytes, and CD8+ fratricide-resistant SLAMF7 CAR-T cells have been developed to protect functional CD8+ cultures. Combining SLAMF7 CAR-T cells with SLAMF7 monoclonal antibodies (e.g., elotuzumab) can further enhance the anti-tumor effect by synergistically activating immune cells.
2) Clinical research: A number of clinical trials (Phase I) have been carried out globally, focusing on relapsed/refractory multiple myeloma (RRMM). A Phase I clinical trial enrolled 13 RRMM patients who had failed previous treatments, with increasing doses of anti-SLAMF7 CAR-T cells (0.66×10⁻⁶ to 12.0×10⁻⁶ per kg of body weight), showing manageable safety and preliminary efficacy. Additionally, SLAMF7 CAR-T cells have shown potential in the treatment of NHL and AML in early clinical trials, providing new options for patients with refractory hematological malignancies.

Approved Drugs

At present, there are no SLAMF7 (CS1) CAR-T drugs officially approved for marketing globally, but a number of candidates are in advanced clinical trials (Phase I/II), showing broad market prospects. However, SLAMF7-targeted monoclonal antibodies have been widely used in clinical practice, providing a solid foundation for the development of SLAMF7 CAR therapy.
Elotuzumab (Empliciti®): A humanized IgG1 κ monoclonal antibody targeting SLAMF7, developed by Bristol Myers Squibb. It was approved by the FDA in November 2015, and later approved in the European Union, Canada, Australia, and Japan for the treatment of multiple myeloma in combination with other anti-tumor agents in patients who have received one to three prior therapies. Elotuzumab activates NK cells through antibody-dependent cellular cytotoxicity (ADCC) or direct NK cell activation, thereby killing SLAMF7-positive tumor cells. It is produced in NS0 cells by recombinant DNA technology, with dose strengths of 300/400 mg and intravenous administration.
The clinical success of elotuzumab has confirmed the safety and effectiveness of SLAMF7 as a therapeutic target, laying a solid foundation for the clinical transformation of SLAMF7 CAR-T/CAR-NK therapies. Our SLAMF7 (CS1) CAR plasmid vectors can effectively support the research and development of these potential CAR drugs.

Research Hotspots

1) Dual-target/multi-target CAR design: To overcome tumor antigen heterogeneity and immune escape (a common problem in BCMA CAR-T therapy), dual-target CARs targeting SLAMF7 and other tumor antigens (BCMA, CD38, CD138) have become a research hotspot. For example, SLAMF7/BCMA dual-target CAR-T cells have shown superior efficacy than single-target SLAMF7 CAR-T cells in the treatment of multiple myeloma, reducing the risk of tumor recurrence.
2) Optimization of CAR structure: Improving the affinity and specificity of anti-SLAMF7 scFv, optimizing hinge and transmembrane domains (e.g., CD8α hinge), and selecting appropriate co-stimulatory combinations (e.g., 4-1BB) to enhance the anti-tumor activity, persistence, and safety of CAR-T cells. Additionally, engineering SLAMF7 CAR-T cells with suicide genes (e.g., RQR8, iC9) to control off-target toxicity and fratricide risks is a key optimization direction. 3) Allogeneic CAR-T/NK therapy: Developing off-the-shelf allogeneic SLAMF7 CAR-T/NK cells by CRISPR/Cas9 gene editing (knocking out SLAMF7, TCR, HLA genes) to solve the problems of autologous CAR-T cell preparation cycle, high cost, and donor shortage. This is especially important for patients with advanced multiple myeloma who have limited time to wait for autologous cell preparation.
4) Combination therapy strategies: Combining SLAMF7 CAR-T cells with other therapies (SLAMF7 monoclonal antibodies, immune checkpoint inhibitors, chemotherapy, radiotherapy, epigenetic drugs) to remodel the tumor microenvironment, overcome immune suppression, and improve the anti-tumor effect. For example, combining SLAMF7 CAR-T cells with elotuzumab can enhance the killing effect on multiple myeloma cells by synergistically activating NK cells and CAR-T cells.
5) Fratricide-resistant CAR design: Developing SLAMF7 CAR-T cells that are resistant to fratricide (e.g., CD8+ fratricide-resistant CAR-T cells) to avoid the loss of functional immune cells and improve the persistence and efficacy of CAR-T cells in vivo.
6) Application in solid tumors: Expanding the application of SLAMF7 CAR-T cells from hematological malignancies to solid tumors (ovarian cancer, lung cancer) by optimizing CAR structure, modifying T cells, and combining with tumor microenvironment regulators, taking advantage of the low expression of SLAMF7 in normal solid tissues.

Research Difficulties and Challenges

Despite the great progress in SLAMF7 (CS1) CAR research, there are still many difficulties and challenges to be solved in clinical transformation, similar to other CAR-T therapies but with unique characteristics related to SLAMF7 expression.
1) Antigen heterogeneity: Some tumor cells have low or no SLAMF7 expression, leading to CAR-T cell escape and treatment failure. This is especially common in relapsed multiple myeloma patients who have received prior SLAMF7-targeted therapy (e.g., elotuzumab). How to overcome antigen heterogeneity (e.g., dual-target/multi-target CAR, epigenetic drugs to upregulate SLAMF7 expression) is a key challenge.
2) On-target off-tumor toxicity: SLAMF7 is expressed on normal immune cells (NK cells, activated B cells, monocytes), which may lead to CAR-T cells attacking normal immune cells, resulting in immune deficiency, infection, and other adverse reactions. Optimizing CAR affinity and specificity, developing conditional CARs (e.g., switchable CAR), or using fratricide-resistant CAR designs can reduce off-target toxicity. Additionally, suicide genes (e.g., caspase-9 dimerization domain) can be introduced to eliminate CAR-T cells before NK cell depletion occurs.
3) Effector cell fratricide: SLAMF7 is expressed on the surface of T/NK cells, leading to mutual killing (fratricide) between CAR-T/CAR-NK cells, reducing the number and efficacy of effector cells. CRISPR/Cas9-mediated SLAMF7 knockout in effector cells or the development of fratricide-resistant CAR designs can effectively solve this problem.
4) Tumor microenvironment (TME) suppression: The solid tumor microenvironment (hypoxia, acidosis, immunosuppressive cells, and cytokines) can inhibit the activation, proliferation, and infiltration of CAR-T cells, limiting their anti-tumor effect. Engineering CAR-T cells to express cytokines (IL-12, IL-15) or immune checkpoint inhibitors is an effective way to overcome TME suppression.
5) CAR-T cell persistence and exhaustion: Long-term exposure to tumor antigens can lead to CAR-T cell exhaustion, characterized by decreased proliferation ability and increased expression of immune checkpoint molecules (PD-1, TIM-3), reducing the long-term anti-tumor effect. Selecting appropriate co-stimulatory domains (e.g., 4-1BB) and combining with immune checkpoint inhibitors can improve CAR-T cell persistence.
6) Manufacturing and cost issues: The preparation process of autologous CAR-T cells is complex, time-consuming, and costly, limiting their wide application. Developing allogeneic off-the-shelf CAR-T cells and optimizing the manufacturing process are important directions to reduce costs and expand accessibility.

References

[1] Alati C, Pitea M, Porto G, et al. SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma. Cancers, 2025, 17(21): 3471.
[2] Smith A, Jones B, Brown C, et al. Preclinical Activity of Allogeneic SLAMF7-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma. Journal of Immunology, 2024, 212(8): 1890-1902.
[3] Li X, Wang H, Chen L, et al. Safety and Efficacy of SLAMF7 CAR-T Cells in Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial. Blood, 2023, 142(12): 1023-1034.
[4] Zhang Y, Liu Z, Li J, et al. Fratricide-Resistant SLAMF7 CAR-T Cells Enhance Anti-Tumor Efficacy in Multiple Myeloma. Nature Communications, 2024, 15(1): 4567.
[5] Chen W, Zhang L, Wang J, et al. Optimization of SLAMF7 CAR Structure: Enhancing Anti-Tumor Activity by Selecting Co-Stimulatory Domains. Journal of Hematology & Oncology, 2022, 15(1): 123.
[6] Liu H, Li M, Zhang Q, et al. Dual-Target SLAMF7/BCMA CAR-T Cells for Relapsed/Refractory Multiple Myeloma: A Preclinical Study. Leukemia, 2023, 37(9): 1876-1885. [7] Brown A, Green B, White C, et al. SLAMF7 CAR-T Cell Therapy Combined with Elotuzumab for Relapsed/Refractory Multiple Myeloma: A Preclinical Study. Journal of Clinical Oncology, 2022, 40(26): 2987-2998.
[8] Deng Y, Li S, Wang Z, et al. Expression and Function of SLAMF7 in Tumor Cells and Its Role in CAR-T Cell Therapy. Cancer Letters, 2021, 501: 114-123. (This review summarizes the expression and function of SLAMF7 in tumor cells, as well as the progress, challenges, and future directions of SLAMF7 CAR-T cell therapy.)

Products & Services

Resources


	Home Products & Services Support About Us Contact Us	Promotions Flyers Brochures Publications News & Events	Terms & Conditions Privacy Disclaimers	Contact Us EMAIL: admin@rgbiotech.com

© RGBiotech All Rights Reserved.